CPT code 55708 represents a transrectal ultrasound–guided prostate biopsy that combines systematic sextant sampling with MRI–ultrasound fusion to target a suspicious lesion. This composite approach blends standard mapped sampling with precision targeting, improving lesion localization and diagnostic yield for suspected prostate cancer. Nationally, the code is relevant as image-fusion biopsy techniques become more widely available and as payers assess medical necessity and coverage for advanced diagnostic procedures.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the procedure, the typical sites of service, and how this code is positioned relative to other prostate biopsy services. The publication presents benchmarks for utilization and reimbursement where available, summaries of payer coverage considerations and coding guidance, and notes on clinical implications for diagnostic accuracy and workflow. Data not available in the input is explicitly identified where applicable. The summary equips billing managers, revenue cycle staff, and policy analysts with the information needed to understand service classification and payer relevance for CPT code 55708.